OncoSil Medical Ltd News

OncoSil Medical Treats Fifth Pancreatic Cancer Patient With Proprietary Device

OncoSil Medical (ASX:OSL) treated the fifth patient in the PANCOSIL trial with its proprietary OncoSil device, the pancreatic cancer treatment device company said in a Tuesday filing with the Australi

MT NewswiresJun 10 20:09 ET

Oncosil Medical Treats 200th Pancreatic Cancer Patient With Proprietary Device

Oncosil Medical (ASX:OSL) completed the treatment of 200 patients of pancreatic cancer with the OncoSil device, according to a Monday filing with the Australian bourse. The OncoSil device is a disposa

MT NewswiresJun 2 21:07 ET

OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial

OncoSil Medical (ASX:OSL) treated two more patients in the Netherlands using its implantable pancreatic cancer device, according to an April 17 filing with the Australian bourse. The treatment is part

MT NewswiresApr 17 18:52 ET

OncoSil Medical Treats First Commercial Patient in Turkey With Implantable Pancreatic Cancer Device

OncoSil Medical (ASX:OSL) treated the first commercial patient in Turkey with its implantable OncoSil pancreatic cancer therapy device, according to a Tuesday filing with the Australian Securities Exc

MT NewswiresApr 15 20:53 ET

OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study

OncoSil Medical (ASX:OSL) on Friday announced the first patient treatment in the UK that utilized its pancreatic cancer device for its TRIPP-FXX clinical study. The study aims to assess the safety and

MT NewswiresApr 11 23:29 ET

OncoSil Medical Obtains Device Reimbursement Approval in UK

OncoSil Medical (ASX:OSL) announced on Tuesday that its device can now be reimbursed at Imperial College Healthcare NHS Trust following an agreement with a large private insurance company in the UK, a

MT NewswiresApr 8 22:19 ET

First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device

OncoSil Medical (ASX:OSL) has penetrated another European market as two Austria-based patients received treatment using the OncoSil device for pancreatic cancer, according to a Friday filing with the

MT NewswiresApr 4 18:52 ET

Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer

Oncosil Medical (ASX:OSL) secured commitments to raise up to a total of AU$7.1 million via a placement to "sophisticated and professional investors" and a non-renounceable entitlement offer. The pancr

MT NewswiresMar 19 23:02 ET

Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade

Australian shares ended their eight-day winning streak on Thursday, tracking the losses of their Wall Street peers after the US Federal Reserve doused market hopes of a March rate cut. The S&P/ASX 200

MT NewswiresFeb 1 00:45 ET

OncoSil Device Included in German Funding Program Negotiations; Shares Jump 14%

Oncosil Medical (ASX:OSL) said Thursday that the German Institute for the Hospital Remuneration System (InEK) approved 84 hospitals to engage in discussions for the inclusion of the OncoSil device in

MT NewswiresJan 31 23:45 ET

OncoSil Strikes Exclusive Distribution Deal For Turkish Market; Shares Jump 14%

Oncosil Medical (ASX:OSL) signed an exclusive three-year distribution agreement with specialist healthcare services company EDH Nuclear Medicine & Healthcare Services, the medical device company said

MT NewswiresJan 31 23:11 ET

OncoSil Device Draws Interest From 84 German Hospitals as Funding Talks Begin

OncoSil Medical (ASX:OSL) a company specializing in localised treatments for locally advanced pancreatic cancer (LAPC), has announced positive developments regarding potential funding for its OncoSil device in Germany and a new distribution agreement in Turkey.

The Market HeraldJan 31 21:44 ET

OncoSil Medical Receives AU$1.1 Million R&D Tax Rebate

OncoSil Medical (ASX:OSL) received a research and development tax refund of AU$1.1 million for eligible activities in fiscal 2023. The funding will help in the continued development of the company's c

MT NewswiresDec 15, 2023 02:23 ET

Stocks of the Hour: Lincoln Minerals, OncoSil Medical, Avira Resources

Lincoln Minerals (ASX:LML) has increased their Kookaburra Gully Graphite Project resource by 87% to become the second largest graphite resource on Eyre Peninsula. Lincoln Minerals CEO Jonathon Trewart

sharecafeDec 7, 2023 19:50 ET

First Patient Treated in OncoSil Medical's Pancreatic Cancer Drug Trial

Medical device company Oncosil Medical (ASX:OSL) said Wednesday that the first patient was treated in the PANCOSIL investigator-initiated clinical trial on Nov. 28, which aimed to treat advanced pancr

MT NewswiresNov 28, 2023 23:49 ET

Australian Shares Rise on Expectations of Easing October CPI

Australian shares reported a small gain on Friday amid expectations of an easing in the Australian Consumer Price Index indicator in October. The S&P/ASX 200 Index climbed 11.60 points, or 0.2%, to 7,

MT NewswiresNov 24, 2023 00:41 ET

OncoSil Medical Secures Insurer Clearance for Pancreatic Cancer Device in Israel

OncoSil Medical (ASX:OSL) secured clearance from insurance firm Clalit General Health Services in Israel for the use of the OncoSil medical device as an "appropriate treatment" for pancreatic cancer.

MT NewswiresNov 23, 2023 23:29 ET

Oncosil Medical Appoints Incoming Chair

OncoSil Medical Ltd (ASX:OSL) appointed Doug Cubbin as incoming chair. Cubin was appointed nonexecutive director, effective Monday. He will take on the chair role once current chair Otto Buttula steps

MT NewswiresAug 7, 2023 00:26 ET

OncoSil Medical (ASX:OSL) Gains Ethics Committee Approval for PANCOSIL Trial

The Market HeraldJun 5, 2023 00:13 ET

OncoSil Medical (ASX:OSL) Treats First Patient in Italy With Flagship Device

The Market HeraldMay 21, 2023 23:34 ET